Biochim Biophys Acta Rev CancerBiochimica et biophysica acta. Reviews on cancerMurayama Y, Oritani K, Tsutsui S (2015). Novel CD9-targeted therapies in gastric cancer. World J Gastroenterol, 21, 3206-13.Murayama Y, Oritani K, Tsutsui S. Novel CD9-targeted therapies in gastric cancer. World...
the prognosis for advanced or metastatic gastric cancer remains dismal, with a mere 5% to 10% five-year survival rate [106]. Based on the results of the phase III clinical study ToGA, the FDA approved trastuzumab for treating HER2-overexpressing gastric/gastroesophageal junction(G/GEJ...
Resistance mechanisms to HER2-targeted therapies have been investigated in breast cancer [24], but it is unclear if similar mechanisms contribute to resistance of HER2-positive GEA. It has been suggested that downregulation or changes of HER2, or upregulation of other receptor tyrosine kinase ...
Therefore, this study aimed to elucidate the underlying mechanisms of acquired trastuzumab resistance in vitro and investigate the efficacy of HER2-targeted therapies in overcoming trastuzumab resistance in HER2-amplified GC cell lines. We illustrated a novel perspective of the differential biological activi...
Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2) are associated with the development of many tumors. It is currently a crucial treatment for multiple cancers. Advanced in molecular biology and further exploration of
HER2-targeted therapies are also being tested in patients with other solid tumours harbouring HER2 overexpression, and/or amplifications or other mutations of the gene encoding HER2 (), including biliary tract, colorectal, non-small-cell lung and bladder cancers. The experience with gastric cancer ...
the HER2-targeted ADC showed a statistically significant improvement in objective response rate and overall survival versus physician’s choice of paclitaxel or irinotecan in patients with advanced HER2-positive gastric/GEJ cancer who progressed on 2 prior therapies, meeting the primary end point of the...
Gastric cancer (GC) is a leading cause of cancer deaths worldwide. Since the approval of trastuzumab, targeted therapies are emerging as promising treatment options for the disease. This study aimed to explore the molecular segmentation of several known therapeutics targets, human epidermal growth fac...
Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer. e15086 Background: Metastatic Colorectal cancer (mCRC) is the 2nd cause of cancer death worldwide. Repeated cycles of therapies, combined with surgery in oligo-metastatic cases,...
Table 1. Clinical studies evaluating HER2- targeted therapies in SGCs (advanced and adjuvant settings). Author, YearStudy designnumber of patientsgendermean age (age range)hystologyHER2 statusIHC; FISH, NGSsettingtreatmentresponseSurvival outcomesreference Iqbal, 2014 case report 1 M 59 poorly differe...